Filing Flows › Immunocore Holdings (IMCR) › Q3 2026
Immunocore Holdings (IMCR) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 6, 2026
Immunocore Holdings (IMCR) reported revenue of $102M for the third quarter 2026 (Q3 2026), -1% from a year earlier and -12% from the quarter before. Operating margin was -13.3%, net loss $14.2M (13.9% of revenue).
Immunocore Holdings, Q3 2026: revenue $102M (-1% year over year), operating margin -13.3%, net loss $14.2M, operating cash flow $20.1M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $102M | -12% | -1% |
| Operating profit | −$13.6M | — | — |
| Net earnings | −$14.2M | — | — |
| Operating cash flow | $20.1M | +26% | — |
| Free cash flow | $17.7M | +17% | — |
What changed
Revenue was $102.2M in Q3 2026, down 1% year over year and down 12% from the previous quarter.
Operating costs exceeded revenue by $13.6M, an operating margin of -13.3%. Total costs grew 4% against a revenue fall of 1%. The fastest-growing cost line was Cost of revenue (+32%). The quarter ended with a net loss of $14.2M, wider than the previous quarter's $808K loss.
Operating cash flow was $20.1M. Non-cash charges added back $1.1M of depreciation and $9.7M of share-based compensation. Working capital and other items added $23.5M. Capital expenditures of $2.3M left free cash flow of $17.7M.
Questions
What was Immunocore Holdings' revenue in the third quarter 2026?
Immunocore Holdings (IMCR) reported revenue of $102M for the third quarter 2026 (Q3 2026), -1% from a year earlier and -12% from the quarter before.
Was Immunocore Holdings profitable in the third quarter 2026?
Operating loss was $13.6M (-13.3% of revenue) and net loss $14.2M.